116.15
price up icon2.74%   3.10
after-market After Hours: 117.00 0.85 +0.73%
loading
Cidara Therapeutics Inc stock is traded at $116.15, with a volume of 878.45K. It is up +2.74% in the last 24 hours and up +77.00% over the past month. Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
See More
Previous Close:
$113.05
Open:
$113.03
24h Volume:
878.45K
Relative Volume:
1.17
Market Cap:
$2.95B
Revenue:
$302.00K
Net Income/Loss:
$-117.10M
P/E Ratio:
-10.44
EPS:
-11.13
Net Cash Flow:
$-129.13M
1W Performance:
+20.43%
1M Performance:
+77.00%
6M Performance:
+538.01%
1Y Performance:
+994.72%
1-Day Range:
Value
$109.36
$116.99
1-Week Range:
Value
$96.44
$121.21
52-Week Range:
Value
$10.14
$121.21

Cidara Therapeutics Inc Stock (CDTX) Company Profile

Name
Name
Cidara Therapeutics Inc
Name
Phone
858-752-6170
Name
Address
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Name
Employee
73
Name
Twitter
@CidaraThera
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
CDTX's Discussions on Twitter

Compare CDTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CDTX
Cidara Therapeutics Inc
116.15 2.87B 302.00K -117.10M -129.13M -11.13
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.37 104.55B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
464.95 60.36B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
557.73 59.84B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
799.56 49.07B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
327.03 35.16B 4.56B -176.77M 225.30M -1.7177

Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-10-25 Initiated JP Morgan Overweight
Jun-18-25 Resumed H.C. Wainwright Buy
Mar-12-25 Initiated Citizens JMP Mkt Outperform
Jan-27-25 Resumed Cantor Fitzgerald Overweight
Dec-13-24 Initiated RBC Capital Mkts Outperform
Nov-08-24 Initiated Guggenheim Buy
Aug-14-24 Upgrade H.C. Wainwright Neutral → Buy
Dec-03-21 Resumed H.C. Wainwright Buy
Sep-22-21 Upgrade WBB Securities Buy → Strong Buy
Mar-04-21 Initiated Aegis Capital Buy
Sep-04-19 Upgrade Wedbush Neutral → Outperform
Jul-26-18 Initiated Citigroup Buy
Apr-21-17 Initiated Raymond James Strong Buy
Apr-17-17 Reiterated H.C. Wainwright Buy
Apr-12-17 Initiated Ladenburg Thalmann Buy
Apr-11-17 Resumed Wedbush Outperform
Feb-22-17 Reiterated H.C. Wainwright Buy
Feb-22-17 Upgrade WBB Securities Sell → Hold
Dec-21-16 Resumed Leerink Partners Outperform
Dec-19-16 Initiated H.C. Wainwright Buy
Sep-23-16 Downgrade WBB Securities Hold → Sell
Oct-09-15 Upgrade WBB Securities Sell → Hold
May-11-15 Initiated Jefferies Buy
May-11-15 Initiated Leerink Partners Outperform
May-11-15 Initiated Needham Buy
May-11-15 Initiated Wedbush Outperform
Apr-23-15 Initiated WBB Securities Sell
View All

Cidara Therapeutics Inc Stock (CDTX) Latest News

pulisher
10:42 AM

Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025 - MarketScreener

10:42 AM
pulisher
10:38 AM

How Cidara Therapeutics Inc. stock benefits from strong dollarPortfolio Return Summary & Fast Gaining Stock Strategy Reports - newser.com

10:38 AM
pulisher
10:23 AM

Can machine learning forecast Cidara Therapeutics Inc. recoveryWeekly Trade Report & Verified Stock Trade Ideas - newser.com

10:23 AM
pulisher
08:54 AM

Cidara to present phase 2 data on influenza drug at ID Week 2025 - Investing.com

08:54 AM
pulisher
08:32 AM

Cidara Therapeutics Inc.’s volatility index tracking explainedDay Trade & AI Powered Market Trend Analysis - newser.com

08:32 AM
pulisher
08:25 AM

How Cidara Therapeutics Inc. stock compares to growth peers2025 EndofYear Setup & Daily Risk Controlled Trade Plans - newser.com

08:25 AM
pulisher
08:13 AM

Cidara Therapeutics to Present Late-Breaking Phase 2 Data on CD388 for Influenza at ID Week 2025 - Quiver Quantitative

08:13 AM
pulisher
08:03 AM

Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025 - The Manila Times

08:03 AM
pulisher
05:48 AM

Can you recover from losses in Cidara Therapeutics Inc.Weekly Profit Summary & Stepwise Trade Execution Plans - newser.com

05:48 AM
pulisher
01:47 AM

Will Cidara Therapeutics Inc. stock deliver long term returns2025 Price Momentum & Risk Managed Trade Strategies - newser.com

01:47 AM
pulisher
01:39 AM

Using Ichimoku Cloud for Cidara Therapeutics Inc. technicals2025 AllTime Highs & Consistent Return Strategy Ideas - newser.com

01:39 AM
pulisher
Oct 12, 2025

What institutional flow reveals about Cidara Therapeutics Inc.Quarterly Trade Report & Verified Momentum Stock Alerts - newser.com

Oct 12, 2025
pulisher
Oct 11, 2025

Cidara Therapeutics (NASDAQ:CDTX) Shares Gap Up on Analyst Upgrade - MarketBeat

Oct 11, 2025
pulisher
Oct 11, 2025

Cidara Therapeutics (NASDAQ:CDTX) Now Covered by JPMorgan Chase & Co. - MarketBeat

Oct 11, 2025
pulisher
Oct 11, 2025

JP Morgan Initiates Coverage on CDTX with Overweight Rating | CD - GuruFocus

Oct 11, 2025
pulisher
Oct 10, 2025

WBB Securities Issues Positive Forecast for Cidara Therapeutics (NASDAQ:CDTX) Stock Price - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza - sharewise.com

Oct 10, 2025
pulisher
Oct 10, 2025

Cidara Therapeutics Analyst Says Lead Influenza Candidate Is 'Strategically Attractive' - Benzinga

Oct 10, 2025
pulisher
Oct 10, 2025

Why Cidara Therapeutics (CDTX) Is Up 12.4% After Breakthrough Therapy Status for Novel Flu Drug CD388 - Yahoo Finance

Oct 10, 2025
pulisher
Oct 10, 2025

Cidara Therapeutics (NASDAQ:CDTX) Hits New 12-Month High Following Analyst Upgrade - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

Cidara Therapeutics (NASDAQ:CDTX) Price Target Raised to $150.00 - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

Cidara Therapeutics Surges Ahead of ESWI 2025 Presentation and JP Morgan Coverage - Benzinga

Oct 10, 2025
pulisher
Oct 10, 2025

Cidara Therapeutics stock price target raised to $150 at H.C. Wainwright - Investing.com Canada

Oct 10, 2025
pulisher
Oct 10, 2025

JP Morgan Initiates Coverage of Cidara Therapeutics (CDTX) with Overweight Recommendation - Nasdaq

Oct 10, 2025
pulisher
Oct 10, 2025

How to build a dashboard for Cidara Therapeutics Inc. stockWeekly Risk Summary & AI Enhanced Trading Signals - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

JPMorgan Initiates Coverage on Cidara Therapeutics With Overweight Rating, $200 Price Target - MarketScreener

Oct 10, 2025
pulisher
Oct 10, 2025

Can Cidara Therapeutics Inc. (20D0) stock reach $200 price target2025 Major Catalysts & Fast Gain Stock Tips - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Forecasting Cidara Therapeutics Inc. price range with options data2025 Volatility Report & Stepwise Swing Trade Plans - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Biotech And Healthcare Stocks Hit 52-Week Highs: Is The Momentum Sustainable? - Nasdaq

Oct 10, 2025
pulisher
Oct 10, 2025

Why Cidara Therapeutics Inc. stock could be next big winnerQuarterly Profit Summary & Long Hold Capital Preservation Tips - newser.com

Oct 10, 2025
pulisher
Oct 09, 2025

Cidara Therapeutics' (CDTX) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat

Oct 09, 2025
pulisher
Oct 09, 2025

Why Cidara Therapeutics Stock Crushed It Today - sharewise.com

Oct 09, 2025
pulisher
Oct 09, 2025

HC Wainwright & Co. Maintains Cidara Therapeutics (CDTX) Buy Recommendation - Nasdaq

Oct 09, 2025
pulisher
Oct 09, 2025

CDTX Surges on FDA's Breakthrough Therapy Designation - GuruFocus

Oct 09, 2025
pulisher
Oct 09, 2025

Cidara Therapeutics Surge: Time to Dive In? - StocksToTrade

Oct 09, 2025
pulisher
Oct 09, 2025

FDA grants breakthrough therapy status to Cidara’s influenza drug By Investing.com - Investing.com Nigeria

Oct 09, 2025
pulisher
Oct 09, 2025

CDTX Analyst Rating Update: WBB Securities Raises Price Target | - GuruFocus

Oct 09, 2025
pulisher
Oct 09, 2025

Cidara Therapeutics stock hits 52-week high at 106.71 USD By Investing.com - Investing.com Nigeria

Oct 09, 2025
pulisher
Oct 09, 2025

CDTX Achieves New Heights: What’s Next? - timothysykes.com

Oct 09, 2025
pulisher
Oct 09, 2025

Cidara Therapeutics Granted FDA Breakthrough Therapy Designation For Flu-Preventing Antiviral - Stocktwits

Oct 09, 2025
pulisher
Oct 09, 2025

Cidara wins FDA “Breakthrough” status for CD388 - The Pharma Letter

Oct 09, 2025
pulisher
Oct 09, 2025

HC Wainwright Maintains Buy Rating on CDTX, Raises Price Target - GuruFocus

Oct 09, 2025
pulisher
Oct 09, 2025

HC Wainwright Raises Cidara Therapeutics' Price Target to $150 From $110, Buy Rating Kept - MarketScreener

Oct 09, 2025
pulisher
Oct 09, 2025

Cidara Therapeutics stock hits 52-week high at 106.71 USD - Investing.com India

Oct 09, 2025
pulisher
Oct 09, 2025

Cidara Therapeutics (CDTX) Gains FDA Breakthrough Designation fo - GuruFocus

Oct 09, 2025
pulisher
Oct 09, 2025

Cidara Therapeutics Receives FDA Breakthrough Therapy Designation for CD388 as Prophylactic Against Influenza A and B - Quiver Quantitative

Oct 09, 2025
pulisher
Oct 09, 2025

Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy - GlobeNewswire

Oct 09, 2025
pulisher
Oct 09, 2025

Breakthrough Therapy for CD388 Granted; Cidara Advances Phase 3 ANCHOR Trial Expanded to Older Adults - Stock Titan

Oct 09, 2025
pulisher
Oct 09, 2025

What hedge fund moves indicate for Cidara Therapeutics Inc. (20D0) stock2025 Sector Review & Fast Exit/Entry Strategy Plans - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

How Cidara Therapeutics Inc. (20D0) stock performs in volatility spikesJuly 2025 Sentiment & Weekly Market Pulse Alerts - newser.com

Oct 09, 2025
pulisher
Oct 08, 2025

Is Cidara Therapeutics Inc a good long term investmentDividend Reinvestment Plans & Big Profit Low Investment - earlytimes.in

Oct 08, 2025

Cidara Therapeutics Inc Stock (CDTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Cidara Therapeutics Inc Stock (CDTX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
RA CAPITAL MANAGEMENT, L.P.
Director
Jun 26 '25
Buy
44.00
2,272,727
99,999,988
3,365,523
Mineo Chrysa
Director
Jun 02 '25
Buy
21.71
2,270
49,281
2,270
Mineo Chrysa
Director
Jun 03 '25
Buy
23.44
1,050
24,614
3,320
Ward Shane
COO & CLO
Mar 11 '25
Sale
21.96
1,664
36,542
14,674
Tari Leslie
CHIEF SCIENTIFIC OFFICER
Mar 11 '25
Sale
21.96
1,773
38,940
16,215
$84.73
price up icon 1.11%
$22.93
price up icon 7.40%
$32.68
price up icon 2.73%
$102.30
price up icon 0.24%
$163.94
price up icon 0.99%
biotechnology ONC
$327.03
price up icon 2.16%
Cap:     |  Volume (24h):